Search

Displaying results 721 - 730 of 10000 in total
  1. Drug

    Alfuzosin

    go.drugbank.com/drugs/DB00346
    Approved

    [L31593] It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies.[L9251]

    Products: ALFUTOR ER TABLETS 10 MG, XATRAL XL 10 MG
  2. Drug

    Tolterodine

    go.drugbank.com/drugs/DB01036
    ApprovedInvestigational

    Tolterodine acts on M2 and M3 subtypes of muscarinic receptors.

    Products: TOLTERODIN HEXAL RET 4 MG, Mylan-tolterodine ER
  3. Drug

    Xylometazoline

    go.drugbank.com/drugs/DB06694
    Approved

    In some countries, it is available as combination products with [ipratropium], [domiphen], or [dexpanthenol].

    Mixtures: nasic - Nasenspray 10 mg/500 mg, nasic - Nasenspray für Kinder 5 mg/500 mgProducts: XILOMETAZOLINA EG, OTRIVINE MENTOL 1 MG/ML DOZ AYARLI BURUN SPREYI, ÇÖZELTİ, 10 ML
  4. Drug

    Palonosetron

    go.drugbank.com/drugs/DB00377
    ApprovedInvestigational

    As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use. … It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of

    Synonyms: 2-(1-Azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz(de)isoquinolin-1-one, (3aS)-2-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinolin-1-oneProducts: SOFT CAPSULES 500 mcg, PALSET (Palonosetron Hydrochloride Solution for Injection 0.05 mg/ml, 5 ml vial)
  5. Drug

    Lapatinib

    go.drugbank.com/drugs/DB01259
    ApprovedInvestigational

    It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. … It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.

    Products: TYKERB 250 MG FILM TABLET, 70 ADET, LAPATINIB EG
  6. Drug

    Lurasidone

    go.drugbank.com/drugs/DB08815
    ApprovedInvestigational

    It was approved by the U.S. … Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States.

    Products: LATUDA® 20 MG TABLETAS RECUBIERTAS, LUİGON 20 MG FİLM KAPLI TABLET, 30 ADET
  7. Drug

    Liraglutide

    go.drugbank.com/drugs/DB06655
    ApprovedInvestigational

    [A6932] Liraglutide was granted FDA approval on January 25, 2010.[L6070] … [Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34.

    Mixtures: Xultophy 100/3.6, XULTOPHY 100U/ML+3.6MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 10 ADETSynonyms: N²⁶-(N-Hexadecanoyl-L-gamma-glutamyl)-[34-L-arginine]glucagon-like peptide 1-(7-37)-peptide
  8. Drug

    Pazopanib

    go.drugbank.com/drugs/DB06589
    ApprovedInvestigational

    It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

    Products: VOTRIENT® 200 MG, Votrient Tablet 200 mg
  9. Drug

    Gefitinib

    go.drugbank.com/drugs/DB00317
    ApprovedInvestigational

    It is marketed by AstraZeneca under the trade name Iressa.

    Products: GEFITINIB EG, GEFTRA® 250 MG
  10. Drug

    Griseofulvin

    go.drugbank.com/drugs/DB00400
    ApprovedVet approved

    Griseofulvin may be given by mouth in the treatment of tinea infections.

    International brands: Grison-250Products: FUNGOVIN 250 MG TABLET, 100 ADET, FUNGOVIN 500 MG TABLET, 100 ADET